Seres Therapeutics Taps Veteran Pharma Exec as Interim CEO Amid Strategic Pivot
Event summary
- Richard N. Kender, former Merck executive, appointed Executive Chair and Interim CEO of Seres Therapeutics.
- Company focuses on live biotherapeutic programs for inflammatory and immune diseases, with SER-155 Phase 2 ready pending funding.
- SER-155 investigator-sponsored study results expected in Q2 2026 for immune checkpoint-related enterocolitis.
- Seres has $45.8 million in cash as of December 31, 2025, with runway through Q3 2026.
The big picture
Seres Therapeutics is undergoing a strategic shift under new interim leadership, focusing on live biotherapeutics for inflammatory and immune diseases. The appointment of Richard N. Kender, with his extensive business development background, signals a push for partnerships and funding to advance key programs. The company's financial runway and upcoming clinical data readouts will be critical in determining its trajectory in the competitive biotech landscape.
What we're watching
- Funding Strategy
- Whether Seres can secure funding to advance SER-155 into Phase 2 trials for allo-HSCT.
- Clinical Data Impact
- How the Q2 2026 SER-155 study results will influence potential strategic partnerships.
- Executive Transition
- The effectiveness of Richard Kender's leadership in driving business development and licensing deals.
Related topics